Published in J Clin Oncol on October 01, 1997
Rituximab in the Treatment of Patients With Bullous Pemphigoid | NCT00286325
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol (2009) 3.07
Rituximab: mechanism of action. Semin Hematol (2010) 2.66
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology (2007) 1.75
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis (2002) 1.74
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood (2012) 1.68
Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol (1998) 1.58
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood (2008) 1.55
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest (2011) 1.50
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol (2008) 1.48
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A (2008) 1.34
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood (2012) 1.31
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk (2012) 1.28
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology (1999) 1.22
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol (2015) 1.16
CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. J Clin Oncol (1998) 1.13
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol (2007) 1.12
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood (2005) 1.08
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood (2009) 1.08
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 1.08
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol (2009) 1.07
GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma (2013) 1.05
Management of indolent lymphoma: where are we now and where are we going. Blood Rev (2012) 1.02
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica (2010) 0.99
Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Hematol Oncol (2011) 0.98
Rituximab-induced coronary vasospasm. Case Rep Hematol (2012) 0.96
Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol (2015) 0.89
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res (2015) 0.88
Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag (2010) 0.88
Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc Natl Acad Sci U S A (1999) 0.87
Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab. Int J Clin Oncol (2005) 0.86
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis. Oncologist (2016) 0.84
Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr (2007) 0.84
Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS One (2012) 0.83
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Clin Immunol (2014) 0.82
Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood (2016) 0.82
Innovative strategies in lymphoma therapy. Wien Klin Wochenschr (2003) 0.81
Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol (2013) 0.81
The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther (2010) 0.80
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother (2016) 0.80
Expanded use of rituximab in the management of non-Hodgkin lymphoma. Onco Targets Ther (2009) 0.78
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics. Eur J Nucl Med Mol Imaging (2005) 0.78
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer (2011) 0.78
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. Cancer Manag Res (2015) 0.78
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) (2016) 0.78
Rituximab for the treatment of patients with chronic lymphocytic leukemia. Cancer Manag Res (2010) 0.77
Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One (2011) 0.76
A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection. Int J Organ Transplant Med (2011) 0.76
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol (2012) 0.76
RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY. Curr Pediatr Rev (2009) 0.76
Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget (2015) 0.76
Refractory Sweet's syndrome successfully treated with rituximab. JAAD Case Rep (2015) 0.75
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. Chin J Cancer Res (2016) 0.75
Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group. J Korean Surg Soc (2012) 0.75
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J Blood Med (2010) 0.75
Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system. Exp Ther Med (2010) 0.75
Theragnostic ultrasound using microbubbles in the treatment of prostate cancer. Ultrasonography (2016) 0.75
Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy. World J Gastroenterol (2005) 0.75
Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report. Open Rheumatol J (2012) 0.75
Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncol Lett (2016) 0.75
Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature. J Med Case Rep (2013) 0.75
Limited Stage Follicular Lymphoma: Current Role of Radiation Therapy. Mediterr J Hematol Infect Dis (2016) 0.75
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. Clin Cancer Res (2016) 0.75
Introduction to monoclonal antibodies. Cancer Immun (2012) 0.75
Fixed Dosing of Monoclonal Antibodies in Oncology. Oncologist (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Two populations of Ia-like molecules on a human B cell line. J Immunol (1980) 7.68
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
Guidelines for laparoscopic (TAPP) and endoscopic (TEP) treatment of inguinal hernia [International Endohernia Society (IEHS)]. Surg Endosc (2011) 6.21
Synthetic lac operator DNA is functional in vivo. Nature (1976) 5.36
'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol (2000) 5.29
Randomized clinical trial of virtual reality simulation for laparoscopic skills training. Br J Surg (2004) 5.19
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J (1993) 4.44
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry (1993) 3.95
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci U S A (1981) 3.63
Obliquity-paced Pliocene West Antarctic ice sheet oscillations. Nature (2009) 3.42
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol (2001) 2.95
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med (1992) 2.73
Measuring client gains from staff-implemented programs. J Appl Behav Anal (1978) 2.72
Tacrine in Alzheimer's disease. Lancet (1991) 2.67
Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 2.62
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol (1990) 2.60
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1998) 2.57
Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med (2000) 2.55
Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol (1980) 2.54
Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem (1980) 2.52
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 2.48
Complete genome sequence of the genetically tractable hydrogenotrophic methanogen Methanococcus maripaludis. J Bacteriol (2004) 2.47
Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. J Clin Microbiol (1998) 2.42
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol (1999) 2.36
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood (2001) 2.35
A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain (1988) 2.32
The neural system that bridges reward and cognition in humans: an fMRI study. Proc Natl Acad Sci U S A (2002) 2.26
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A (2000) 2.24
Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol (1998) 2.21
The association of genital herpesvirus with cervical atypia and carcinoma in situ. Am J Epidemiol (1970) 2.17
A systematic review of peri-operative melatonin. Anaesthesia (2014) 2.16
Randomized clinical trial of self-gripping mesh versus sutured mesh for Lichtenstein hernia repair. Br J Surg (2012) 2.16
Environmental and biological monitoring for lead exposure in California workplaces. Am J Public Health (1990) 2.16
Enteropathogenic Escherichia coli dephosphorylates and dissociates occludin from intestinal epithelial tight junctions. Cell Microbiol (2000) 2.16
Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther (1982) 2.12
Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia (2003) 2.12
A randomized trial of physical rehabilitation for very frail nursing home residents. JAMA (1994) 2.11
Carbon monoxide re-breathing during low-flow anaesthesia in infants and children. Br J Anaesth (2010) 2.09
Virtual reality computer simulation. Surg Endosc (2001) 2.09
Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain (2001) 2.07
Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc Natl Acad Sci U S A (1978) 2.06
Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy. Cancer (1986) 2.04
Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry (1990) 2.01
Comparison of multidetector CT angiography and MR imaging of cervical artery dissection. AJNR Am J Neuroradiol (2008) 2.01
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res (2000) 2.00
The monoclonality of human B-cell lymphomas. J Exp Med (1977) 1.97
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood (1997) 1.96
A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 1.94
Lewy bodies and response to tacrine in Alzheimer's disease. Lancet (1994) 1.94
The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry (1989) 1.94
Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell (1986) 1.92
Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med (1974) 1.91
Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res (1999) 1.91
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1999) 1.91
A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91
Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant (1999) 1.90
Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis (1995) 1.88
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.87
Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet (1993) 1.87
Cytokines, chemokines and growth factors in endometrium related to implantation. Hum Reprod Update (2005) 1.86
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Accuracy of clinical diagnosis of Alzheimer's disease. BMJ (1990) 1.84
Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed. Psychol Med (1996) 1.84
Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci U S A (1992) 1.82
The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene (1997) 1.81
Early medical use of cannabis. Nature (1993) 1.80
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer (1978) 1.77
Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet (1981) 1.76
Health-related quality of life after laparoscopic and open surgery for rectal cancer in a randomized trial. Br J Surg (2013) 1.76